Clinical Trial Update: A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TMC435350 with or without standard of care in genotype 1 chronic hepatitis C; results from the trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435350

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2014-02-06